SCHEMBL21261107

SCHEMBL21261107

CC1(C)CCc2sc(NC(=O)c3cccc(OC(F)F)c3)c(C(=O)O)c21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 9/20 0.55
▸ MEN1 O00255 8/20 0.55
▸ NOD1 Q9Y239 1/20 0.55
▸ MAPT P10636 7/20 0.48
▸ RAB9A P51151 6/20 0.48
▸ NPSR1 Q6W5P4 3/20 0.48
▸ LMNA P02545 2/20 0.48
▸ SENP8 Q96LD8 1/20 0.48
▸ SENP7 Q9BQF6 1/20 0.48
▸ SENP6 Q9GZR1 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ NPC1 O15118 6/20 0.48
▸ TP53 P04637 1/20 0.48
▸ FLT3 P36888 1/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ GAA P10253 1/20 0.47
▸ POLB P06746 3/20 0.46
▸ ATM Q13315 1/20 0.44
▸ RAB7A P51149 1/20 0.44
▸ TDP1 Q9NUW8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247261 0.90 GLO1 (0.50) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL21253132 0.85 RAB9A (0.58) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL21247321 0.80 NOD1 (0.62) KMT2AMEN1NOD1MAPTLMNA
SCHEMBL21261089 0.79 GLO1 (0.49) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL21247405 0.79 RAB9A (0.62) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL21247238 0.78 MEN1 (0.57) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL21247283 0.78 TNF (0.61) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL21250159 0.75 CNR2 (0.52) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL21260924 0.74 MEN1 (0.74) KMT2AMEN1NOD1MAPTRAB9A
SCHEMBL918754 0.70 MEN1 (0.98) KMT2AMEN1NOD1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
CN-111954668-A Fused thiophene derivative and use thereof 埃尼奥制药公司 2020-11-17 — — CN disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH KMT2A 3454/4885MEN1 3538/4885NOD1 410/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH KMT2A 3454/4885MEN1 3538/4885NOD1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback